Summary

The global stomach cancer treatment market is gaining strong traction as the incidence of gastric cancer continues to rise across the globe. Stomach cancer remains a major health concern, particularly in regions with aging populations and changing lifestyle patterns. Advances in oncology, combined with the increasing adoption of targeted therapies and immunotherapies, are significantly transforming the treatment landscape. According to Persistence Market Research, the market is evolving rapidly with a growing focus on improving survival outcomes and enhancing quality of life for patients. Continuous innovation in drug development and increasing awareness regarding early diagnosis are further contributing to market expansion.

Market Insights

The stomach cancer treatment market is expected to reach USD 6.9 billion in 2026 and is projected to grow to USD 14.5 billion by 2033, registering a CAGR of 11.3% during the forecast period. This substantial growth reflects the increasing burden of gastric cancer and the rising demand for effective and advanced treatment solutions. The market is witnessing a gradual transition from traditional chemotherapy to more sophisticated treatment approaches, including targeted therapies and immunotherapies.

The of biologics and precision medicine is reshaping the market dynamics. Treatments focusing on specific molecular targets such as HER2 and PD-1/PD-L1 pathways are delivering improved clinical outcomes. Moreover, the growing number of regulatory approvals and ongoing clinical trials is accelerating the availability of innovative therapies in the market.

Market Drivers

A key factor driving the stomach cancer treatment market is the rising prevalence of gastric cancer worldwide. Contributing factors such as unhealthy diets, smoking habits, Helicobacter pylori infections, and genetic susceptibility are increasing the disease burden. This has resulted in a heightened need for effective treatment options.

Another significant driver is the rapid progress in biotechnology and pharmaceutical research. The development of targeted therapies and immunotherapies has revolutionized cancer care by offering more precise and less toxic treatment alternatives compared to conventional methods. These therapies are gaining widespread acceptance due to their effectiveness in improving patient outcomes.

In addition, increasing healthcare investments and government initiatives aimed at strengthening cancer care infrastructure are supporting market growth. Enhanced screening programs and awareness campaigns are promoting early diagnosis, which plays a crucial role in improving treatment success rates and survival outcomes.

Business Opportunity

The stomach cancer treatment market presents considerable growth opportunities for industry participants. The shift toward personalized medicine is creating demand for therapies tailored to individual patient profiles. Companies investing in biomarker research and precision oncology are likely to benefit significantly from this trend.

Emerging economies are expected to offer substantial growth potential due to improving healthcare systems and rising access to advanced treatments. Countries in Asia Pacific and Latin America are witnessing increased healthcare expenditure, which is driving the adoption of innovative cancer therapies.

Strategic collaborations and partnerships among pharmaceutical companies, research institutions, and healthcare providers are fostering innovation. The development of combination therapies that integrate chemotherapy, targeted therapy, and immunotherapy is gaining momentum. Additionally, expanding clinical research activities and faster regulatory approvals are expected to bring new treatment options to market.

Region Analysis

Asia Pacific dominates the stomach cancer treatment market, driven by a high prevalence of gastric cancer in countries such as China, Japan, and South Korea. The region benefits from a large patient population, improving healthcare infrastructure, and increasing government initiatives focused on cancer treatment and awareness.

North America represents a significant market share due to advanced healthcare systems, strong research and development capabilities, and early adoption of innovative therapies. The presence of leading pharmaceutical companies and favorable reimbursement policies further support market growth in the region.

Europe also holds a considerable share of the market, supported by well-established healthcare frameworks and a strong focus on cancer research. Increasing awareness and access to advanced treatment options are contributing to steady growth across the region.

Latin America and the Middle East & Africa are emerging markets with growing potential. Improvements in healthcare access, rising awareness, and ongoing investments in medical infrastructure are expected to drive gradual market expansion in these regions.

Key Players

The stomach cancer treatment market is highly competitive, with major players focusing on innovation, product development, and strategic alliances to strengthen their positions. Leading companies in the market include:

• F. Hoffmann-La Roche Ltd.

• Pfizer Inc.

• Eli Lilly and Company

• Novartis AG

• Merck & Co., Inc.

• Bristol-Myers Squibb Company

• AstraZeneca plc

• Bayer AG

• Teva Pharmaceutical Industries Ltd.

• Celltrion Healthcare Co., Ltd.

• Samsung Bioepis

• Amgen Inc.

• Daiichi Sankyo Company, Limited

• Astellas Pharma Inc.

• Ono Pharmaceutical Co., Ltd.

These companies are actively investing in research and development to introduce advanced therapies and expand their product portfolios. Strategic mergers, acquisitions, and partnerships are also being pursued to enhance global market presence.

Segmentation

By Treatment Type

• Standard Chemotherapy

• Targeted Therapy

• Immunotherapy

By Disease Indication

• Gastric Cancer/Gastroesophageal Junction cancer

• Gastrointestinal Stromal Tumors

By Route of Administration

• Oral

• Injectable

By Drug Class

• PD-1/PD-L1 Inhibitors

• HER2 Antagonists

• VEGFR Antgonists

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Stomach Cancer Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Stomach Cancer Treatment Market Outlook, 2020-2033
3.1. Global Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
3.1.1. Standard Chemotherapy
3.1.2. Targeted Therapy
3.1.3. Immunotherapy
3.2. Global Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
3.2.1. Gastric Cancer/Gastroesophageal Junction cancer
3.2.2. Gastrointestinal Stromal Tumors
3.3. Global Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
3.3.1. Oral
3.3.2. Injectable
3.4. Global Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
3.4.1. PD-1/PD-L1 Inhibitors
3.4.2. HER2 Antagonists
3.4.3. VEGFR Antgonists
3.4.4. Others
3.5. Global Stomach Cancer Treatment Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Stomach Cancer Treatment Market Outlook, 2020-2033
4.1. North America Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
4.1.1. Standard Chemotherapy
4.1.2. Targeted Therapy
4.1.3. Immunotherapy
4.2. North America Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
4.2.1. Gastric Cancer/Gastroesophageal Junction cancer
4.2.2. Gastrointestinal Stromal Tumors
4.3. North America Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
4.3.1. Oral
4.3.2. Injectable
4.4. North America Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
4.4.1. PD-1/PD-L1 Inhibitors
4.4.2. HER2 Antagonists
4.4.3. VEGFR Antgonists
4.4.4. Others
4.5. North America Stomach Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.5.1. U.S. Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
4.5.2. U.S. Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
4.5.3. U.S. Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
4.5.4. U.S. Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
4.5.5. Canada Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
4.5.6. Canada Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
4.5.7. Canada Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
4.5.8. Canada Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Stomach Cancer Treatment Market Outlook, 2020-2033
5.1. Europe Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
5.1.1. Standard Chemotherapy
5.1.2. Targeted Therapy
5.1.3. Immunotherapy
5.2. Europe Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
5.2.1. Gastric Cancer/Gastroesophageal Junction cancer
5.2.2. Gastrointestinal Stromal Tumors
5.3. Europe Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
5.3.1. Oral
5.3.2. Injectable
5.4. Europe Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
5.4.1. PD-1/PD-L1 Inhibitors
5.4.2. HER2 Antagonists
5.4.3. VEGFR Antgonists
5.4.4. Others
5.5. Europe Stomach Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.5.1. Germany Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.2. Germany Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.3. Germany Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.4. Germany Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.5. Italy Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.6. Italy Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.7. Italy Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.8. Italy Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.9. France Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.10. France Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.11. France Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.12. France Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.13. U.K. Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.14. U.K. Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.15. U.K. Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.16. U.K. Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.17. Spain Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.18. Spain Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.19. Spain Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.20. Spain Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.21. Russia Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.22. Russia Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.23. Russia Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.24. Russia Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.5.25. Rest of Europe Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
5.5.26. Rest of Europe Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
5.5.27. Rest of Europe Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
5.5.28. Rest of Europe Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Stomach Cancer Treatment Market Outlook, 2020-2033
6.1. Asia Pacific Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
6.1.1. Standard Chemotherapy
6.1.2. Targeted Therapy
6.1.3. Immunotherapy
6.2. Asia Pacific Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
6.2.1. Gastric Cancer/Gastroesophageal Junction cancer
6.2.2. Gastrointestinal Stromal Tumors
6.3. Asia Pacific Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
6.3.1. Oral
6.3.2. Injectable
6.4. Asia Pacific Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
6.4.1. PD-1/PD-L1 Inhibitors
6.4.2. HER2 Antagonists
6.4.3. VEGFR Antgonists
6.4.4. Others
6.5. Asia Pacific Stomach Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.5.1. China Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.2. China Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.3. China Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.4. China Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.5.5. Japan Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.6. Japan Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.7. Japan Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.8. Japan Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.5.9. South Korea Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.10. South Korea Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.11. South Korea Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.12. South Korea Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.5.13. India Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.14. India Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.15. India Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.16. India Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.5.17. Southeast Asia Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.18. Southeast Asia Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.19. Southeast Asia Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.20. Southeast Asia Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.5.21. Rest of SAO Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
6.5.22. Rest of SAO Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
6.5.23. Rest of SAO Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
6.5.24. Rest of SAO Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Stomach Cancer Treatment Market Outlook, 2020-2033
7.1. Latin America Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
7.1.1. Standard Chemotherapy
7.1.2. Targeted Therapy
7.1.3. Immunotherapy
7.2. Latin America Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
7.2.1. Gastric Cancer/Gastroesophageal Junction cancer
7.2.2. Gastrointestinal Stromal Tumors
7.3. Latin America Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
7.3.1. Oral
7.3.2. Injectable
7.4. Latin America Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
7.4.1. PD-1/PD-L1 Inhibitors
7.4.2. HER2 Antagonists
7.4.3. VEGFR Antgonists
7.4.4. Others
7.5. Latin America Stomach Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.5.1. Brazil Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
7.5.2. Brazil Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
7.5.3. Brazil Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
7.5.4. Brazil Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
7.5.5. Mexico Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
7.5.6. Mexico Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
7.5.7. Mexico Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
7.5.8. Mexico Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
7.5.9. Argentina Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
7.5.10. Argentina Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
7.5.11. Argentina Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
7.5.12. Argentina Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
7.5.13. Rest of LATAM Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
7.5.14. Rest of LATAM Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
7.5.15. Rest of LATAM Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
7.5.16. Rest of LATAM Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Stomach Cancer Treatment Market Outlook, 2020-2033
8.1. Middle East & Africa Stomach Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
8.1.1. Standard Chemotherapy
8.1.2. Targeted Therapy
8.1.3. Immunotherapy
8.2. Middle East & Africa Stomach Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2020-2033
8.2.1. Gastric Cancer/Gastroesophageal Junction cancer
8.2.2. Gastrointestinal Stromal Tumors
8.3. Middle East & Africa Stomach Cancer Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
8.3.1. Oral
8.3.2. Injectable
8.4. Middle East & Africa Stomach Cancer Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
8.4.1. PD-1/PD-L1 Inhibitors
8.4.2. HER2 Antagonists
8.4.3. VEGFR Antgonists
8.4.4. Others
8.5. Middle East & Africa Stomach Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.5.1. GCC Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
8.5.2. GCC Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
8.5.3. GCC Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
8.5.4. GCC Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
8.5.5. South Africa Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
8.5.6. South Africa Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
8.5.7. South Africa Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
8.5.8. South Africa Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
8.5.9. Egypt Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
8.5.10. Egypt Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
8.5.11. Egypt Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
8.5.12. Egypt Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
8.5.13. Nigeria Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
8.5.14. Nigeria Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
8.5.15. Nigeria Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
8.5.16. Nigeria Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
8.5.17. Rest of Middle East Stomach Cancer Treatment Market Outlook, by Treatment Type, 2020-2033
8.5.18. Rest of Middle East Stomach Cancer Treatment Market Outlook, by Disease Indication, 2020-2033
8.5.19. Rest of Middle East Stomach Cancer Treatment Market Outlook, by Route of Administration, 2020-2033
8.5.20. Rest of Middle East Stomach Cancer Treatment Market Outlook, by Drug Class, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. F. Hoffmann-La Roche Ltd.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Pfizer Inc.
9.4.3. Eli Lilly and Company
9.4.4. Novartis AG
9.4.5. Merck & Co., Inc.
9.4.6. Bristol-Myers Squibb Company
9.4.7. AstraZeneca plc
9.4.8. Bayer AG
9.4.9. Teva Pharmaceutical Industries Ltd.
9.4.10. Celltrion Healthcare Co., Ltd.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations